Literature DB >> 28882225

Animal Models to Study MicroRNA Function.

Arpita S Pal1, Andrea L Kasinski2.   

Abstract

The discovery of the microRNAs, lin-4 and let-7 as critical mediators of normal development in Caenorhabditis elegans and their conservation throughout evolution has spearheaded research toward identifying novel roles of microRNAs in other cellular processes. To accurately elucidate these fundamental functions, especially in the context of an intact organism, various microRNA transgenic models have been generated and evaluated. Transgenic C. elegans (worms), Drosophila melanogaster (flies), Danio rerio (zebrafish), and Mus musculus (mouse) have contributed immensely toward uncovering the roles of multiple microRNAs in cellular processes such as proliferation, differentiation, and apoptosis, pathways that are severely altered in human diseases such as cancer. The simple model organisms, C. elegans, D. melanogaster, and D. rerio, do not develop cancers but have proved to be convenient systesm in microRNA research, especially in characterizing the microRNA biogenesis machinery which is often dysregulated during human tumorigenesis. The microRNA-dependent events delineated via these simple in vivo systems have been further verified in vitro, and in more complex models of cancers, such as M. musculus. The focus of this review is to provide an overview of the important contributions made in the microRNA field using model organisms. The simple model systems provided the basis for the importance of microRNAs in normal cellular physiology, while the more complex animal systems provided evidence for the role of microRNAs dysregulation in cancers. Highlights include an overview of the various strategies used to generate transgenic organisms and a review of the use of transgenic mice for evaluating preclinical efficacy of microRNA-based cancer therapeutics.
© 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Caenorhabditis elegans; Cancer; Danio rerio; Drosophila melanogaster; Fruit fly; Function; GEMMs; In vivo; MicroRNA; Model systems; Mouse; Mus musculus; Transgenic; Zebrafish

Mesh:

Substances:

Year:  2017        PMID: 28882225      PMCID: PMC5860655          DOI: 10.1016/bs.acr.2017.06.006

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  248 in total

1.  Effect of miR-34b overexpression on the radiosensitivity of non-small cell lung cancer cell lines.

Authors:  Joana Balça-Silva; Sílvia Sousa Neves; Ana Cristina Gonçalves; Ana Margarida Abrantes; João Casalta-Lopes; Maria Filomena Botelho; Ana Bela Sarmento-Ribeiro; Henriqueta Coimbra Silva
Journal:  Anticancer Res       Date:  2012-05       Impact factor: 2.480

Review 2.  Current advances in humanized mouse models.

Authors:  Ryoji Ito; Takeshi Takahashi; Ikumi Katano; Mamoru Ito
Journal:  Cell Mol Immunol       Date:  2012-02-13       Impact factor: 11.530

3.  miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.

Authors:  Andrea L Kasinski; Frank J Slack
Journal:  Cancer Res       Date:  2012-09-10       Impact factor: 12.701

4.  MicroRNA miR-7 is preferentially expressed in endocrine cells of the developing and adult human pancreas.

Authors:  Mayrin Correa-Medina; Valia Bravo-Egana; Samuel Rosero; Camillo Ricordi; Helena Edlund; Juan Diez; Ricardo L Pastori
Journal:  Gene Expr Patterns       Date:  2008-12-24       Impact factor: 1.224

5.  The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.

Authors:  Ulf Klein; Marie Lia; Marta Crespo; Rachael Siegel; Qiong Shen; Tongwei Mo; Alberto Ambesi-Impiombato; Andrea Califano; Anna Migliazza; Govind Bhagat; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2010-01-07       Impact factor: 31.743

6.  Suppression of non-small cell lung tumor development by the let-7 microRNA family.

Authors:  Madhu S Kumar; Stefan J Erkeland; Ryan E Pester; Cindy Y Chen; Margaret S Ebert; Phillip A Sharp; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

7.  Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding.

Authors:  Aleksandra Helwak; Grzegorz Kudla; Tatiana Dudnakova; David Tollervey
Journal:  Cell       Date:  2013-04-25       Impact factor: 41.582

8.  Plasma exosome microRNAs are indicative of breast cancer.

Authors:  Bethany N Hannafon; Yvonne D Trigoso; Cameron L Calloway; Y Daniel Zhao; David H Lum; Alana L Welm; Zhizhuang J Zhao; Kenneth E Blick; William C Dooley; W Q Ding
Journal:  Breast Cancer Res       Date:  2016-09-08       Impact factor: 6.466

9.  Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells.

Authors:  Yoshimasa Saito; Jeffrey M Friedman; Yoshitomo Chihara; Gerda Egger; Jody C Chuang; Gangning Liang
Journal:  Biochem Biophys Res Commun       Date:  2008-12-29       Impact factor: 3.322

10.  Imperfect centered miRNA binding sites are common and can mediate repression of target mRNAs.

Authors:  Hilary C Martin; Shivangi Wani; Anita L Steptoe; Keerthana Krishnan; Katia Nones; Ehsan Nourbakhsh; Alexander Vlassov; Sean M Grimmond; Nicole Cloonan
Journal:  Genome Biol       Date:  2014-03-14       Impact factor: 13.583

View more
  21 in total

Review 1.  Potential of miRNAs to predict and treat inflammation from the perspective of Familial Mediterranean Fever.

Authors:  Banu Balci-Peynircioglu; Yeliz Z Akkaya-Ulum; Tayfun Hilmi Akbaba; Zeynep Tavukcuoglu
Journal:  Inflamm Res       Date:  2019-07-24       Impact factor: 4.575

2.  Effect of miR-101 on the Proliferation and Apoptosis of Goat Hair Follicle Stem Cells.

Authors:  Jingwen Qu; Xi Wu; Qiang Wang; Jian Wang; Xiaomei Sun; Dejun Ji; Yongjun Li
Journal:  Genes (Basel)       Date:  2022-06-09       Impact factor: 4.141

3.  miRNA-22 as a Candidate Diagnostic Biomarker for Coronary Slow Flow.

Authors:  Tong Chen; Zhen-Yu Wang; Chuan-Chang Li
Journal:  Cardiol Res Pract       Date:  2020-07-26       Impact factor: 1.866

Review 4.  microRNA-based diagnostic and therapeutic applications in cancer medicine.

Authors:  Lorenzo F Sempere; Asfar S Azmi; Anna Moore
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-05-17       Impact factor: 9.957

5.  Barriers in systemic delivery and preclinical testing of synthetic microRNAs in animal models: an experimental study on miR-215-5p mimic.

Authors:  T Machackova; P Vychytilova-Faltejskova; K Souckova; R Laga; L Androvič; G Mixová; O Slaby
Journal:  Physiol Res       Date:  2021-05-12       Impact factor: 1.881

Review 6.  Digging into bivalve miRNAomes: between conservation and innovation.

Authors:  Umberto Rosani; Enrico Bortoletto; Chang-Ming Bai; Beatriz Novoa; Antonio Figueras; Paola Venier; Bastian Fromm
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2021-04-05       Impact factor: 6.671

Review 7.  MicroRNA Regulation of Host Immune Responses following Fungal Exposure.

Authors:  Tara L Croston; Angela R Lemons; Donald H Beezhold; Brett J Green
Journal:  Front Immunol       Date:  2018-02-07       Impact factor: 7.561

8.  Methods to Investigate miRNA Function: Focus on Platelet Reactivity.

Authors:  Alix Garcia; Sylvie Dunoyer-Geindre; Richard J Fish; Marguerite Neerman-Arbez; Jean-Luc Reny; Pierre Fontana
Journal:  Thromb Haemost       Date:  2020-10-29       Impact factor: 5.249

9.  Parallel analysis of miRNAs and mRNAs suggests distinct regulatory networks in Crassostrea gigas infected by Ostreid herpesvirus 1.

Authors:  Umberto Rosani; Miriam Abbadi; Timothy Green; Chang-Ming Bai; Edoardo Turolla; Giuseppe Arcangeli; K Mathias Wegner; Paola Venier
Journal:  BMC Genomics       Date:  2020-09-10       Impact factor: 3.969

Review 10.  Role of MicroRNAs Induced by Chinese Herbal Medicines Against Hepatocellular Carcinoma: A Brief Review.

Authors:  Ge Guo; Juhua Zhou; Xiaogaung Yang; Jiang Feng; Yanxia Shao; Tingting Jia; Qingrong Huang; Yanmin Li; Yin Zhong; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  Integr Cancer Ther       Date:  2018-10-20       Impact factor: 3.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.